Transcript RHD
Fetal RHD a RHCE status determination from
maternal circulation, alloimmunisation
Prof. Ilona Hromadnikova, PhD.
Department of Molecular Biology and Cell
Pathology
Alloimmunisation – production of maternal
antibodies against Ags on fetal erythrocytes
Placental transfer of IgG
Destruction of fetal erythrocytes
→ Erythroblastosis fetalis and HDN is most often
caused by incompatibility in RhD system
Anti-c, anti-E, anti-C, anti-e
Alloantibodies x other blood group
antigens
Lewis (Lea, Leb)
Kidd (Jka, Jkb)
Diego (Dia, Dib)
Duffy (Fya, Fyb)
MNSs (M, N, S, s, U)
Lutheran (Lua, Lub)
AB0 incompatibility (women 0, man A
or B; anti-A, anti-B IgG production, rare
intrauterine hemolysis,
hyperbilirubinemia postnatally,
risk of icterus
E. Sjoberg-Wester; Jill Storry
RHD gene – many variants
In the Czech republic – most common variants:
D VI, DFR, D VII, DCS
Rearrangement between RHD and RHCE genes, point
mutations
Frequency – about 1% in Caucasian population
RhD variant protein – absence of 1 or more epitopes
→ women is laboratorally positive but can produce
anti-D antibodies against „missing epitopes“
Women with variant RhD protein – considered as RhD
negative, can cause HDN
Lower expression of RhD protein (weak RhD, Du) on
erythrocyte surface, but with more or less full D
epitope „repertoire“
(could be serologically negative with weak Rh
positivity)
Patients with weak RhD antigen – no production of
anti-D Abs, no risk of HDN
Prophylaxis not necessary
Incompatible blood transfusion
In previous pregnancy –passage of fetal
cells into maternal circulation
Invasive procedure(CVS, AMC, cordocentesis)
Miscarriage
Delivery
Bleeding during pregnancy
Colour Atlas of Immunology
IgG active transport (all 4 subclasses of
alloantibodies) across the placenta
Abs transport– low till the 20th week of gestation, then
exponential increase
30th week – ½ of serum maternal concentration [IgG]
At time of delivery: [IgG] in fetal circulation about 10%
higher than in maternal serum
IgG – transcytosis via syncytiotrophoblast cells
1. active process using receptor
2. pinocytosis
Vesicle fusion, in endosomes↓ pH – binding to FcRn
(IgG unbound – lysosomal degradation)
Exocytosis on the basal surface, diffusion to fetal
circulation
Colour Atlas of
Immunology
Immunopathological reaction type II – cytotoxic Abs
ADCC (antibody-dependent cell-mediated
cytotoxicity ) → destruction of fetal erythrocytes by
splenic macrophages
1.
2.
3.
3 stages:
Anemia neonatorum – low levels of Hb and
hematocrit
Icterus neonatorum (more serious anaemia,
hepatosplenomegaly, without treatment – bilirubin
encephalopathy)
Hydrops fetalis(generalized edema of the fetus
with fluid accumulation in the body cavities, very
bad prognosis)
Danger of anaemia – positive indirect antiglobulin
(Coombs) test
Detection of 1 or more Abs associated with HDN in
maternal serum
Colour Atlas of
Immunology
First screening between 10th and 12th week of
gestation, all pregnant women
Determination of maternal blood group
Negativity – again in the 24th and 32nd week
Positivity – determination of Ab specificity and titer
1:8 and higher – repetition every month
titre 1:16 and higher for anti-D Ab; 1:8 for Kell Ab and
higher – risk of HDN
Antibodies present (Indirect Coombs test positive)
Father homo/heterozygosity in RHD gene
homozygote
Noninvasive RhD status determination
Heterozygote,
50% probability of fetal
RhD positivity
RhD negative
RhD positive
At anti-D alloimmunized RhD negative
pregnant women at risk of HDN
RhD negativity – deletion of RHD gene in
Caucasian population
RHD (pseudogene)
Complete inactive RHD gene, 37-bp insertion in
exon 4 (PCR) + 1-2 stop codons in exon 6,
earlier termination of translation, 0 HON
66% of Africans, 27,7% Japaneses and11% of
Brazilian
Hybrid RHD-CE-D gene
RhD negative phenotype: 3´ end of exon 3 a
exons 4-8 of RHCE gene
RHD exon 10 +, exon 7 – (PCR)
Weak C, VS+, Africans (3%)
RHD genotyping– necessary to analyse more
regions of RHD gene
Most often combination of exon 7 and 10 or exon
7 and 5
Interpretation of results together with ethnic group
(incidence of RHD gene alterations)
Our laboratory – combination of exon 7 and 10
with 100 % specificity a 100 % sensitivity
RhD negative foetuses at alloimmunized
pregnancies - not endangered by HDN
RhD positive foetuses – important information for
clinicians
At anti-c alloimmunized CC homozygous
pregnant women at risk of HDN
Determination of fetal Rhc allele
At anti-C alloimmunized cc homozygous pregnant
women at risk of HDN
Determination of fetal RhC alelle
At anti-E alloimmunized ee homozygous pregnant
women at risk of HDN
Determination of fetal RhE allele
At anti-e alloimmunized EE homozygous pregnant
women at risk of HDN
Determination of fetal Rhe alelle
SNP exon 2 (Rhc)
Specific insertion in intron 2 (RhC)
SNP exon 5 (RhE/Rhe)
RHD exon 7 and exon 10, RHCE - C allele
detection with 100 % specificity and 100 %
sensitivity
RHCE - c allele and E allele genotyping (SNP) –
100 % specificity and 95 % sensitivity, more difficult
– most of cell-free DNA is of maternal origin
RhcCE negative foetuses at alloimmunized
pregnancies – not endangered by HDN,
positive foetuses – early information for clinicians
Stage of sensitisation
Titer, specificiy, concentration, avidity and
subclass of IgG
Expression of antigen on erythrocyte surface
(weak RhD antigens)
Gestational age
Presence of „blocking“ antibodies in maternal
serum
→ other examination necessary: ultrasound, Doppler,
cordocenthesis
Spectrophotometric measurement of bilirubin in
amniotic fluid – serial AMC
Not used anymore – intensify immunization
Ultrasound examination
Compensatory reaction
symptoms
(hepatosplenomegaly),
occurrence of ascites,
hydrops)
Queenan et al., 1993
Doppler measurement of the fetal
middle cerebral artery peak
systolic velocity - arteria cerebri
media
In the anemic fetus, low blood
viscosity and increased cardiac
output contribute to an
increased blood velocity, PI
Doubek a kol., 2005
Kenneth, 2004
Cordocenthesis
Mostly used for access to fetal
circulation
Often continue from diagnostic to
therapeutic procedure –
intraumbilical transfusion
Possibility to determine fetal Rh
status and blood count
From the 20th week of gestation,
not convenient after 34th week of
gestation
2 therapeutic alternatives:
1.
Intrauterine transfusion(5% risk)
2.
Preterm delivery
Gestational age
Maturity of lungs
General fetal condition
↑ gestational age - ↓ postnatal risk
Firstly at 1963
Usually intraumbilical transfusion, refill an/or
exchange blood transfusion under ultrasound
control
No consensus about fetal hematocrit– 40 – 65%
But when hematocrit over 50% - ↑ blood viscosity,
hypoxia in some organs
Complications – severe bradycardia
Hájek et al. recommendation
erythrocyte transfusion preparates Hct 80 – 85%
→ final fetal Hct 40 – 45%
From the 20th till the
34th week
7-10 days interval
(shorter in cases of
hydrops fetalis)
Pregnancy termination
in 2-3 week after last
transfusion
Repeated intraumbilical transfusions, latest at 34th
– 35th week of gestation, usually followed by SC
between 37th – 38th week
Intrauterinely bilirubin excreted by placenta
x lower conjugation of higher levels of bilirubin in
fetal liver – increase of indirect bilirubin,
accumulation in basal ganglia
→ icterus – bilirubin encephalopathy
Application of phenobarbital (30 mg per day, 10
days before delivery) – improves bilirubin
metabolism in fetal liver
Immediately after delivery do tests for:
pH and blood gases
Blood group and Rh status
Hemoglobin a hematocrit
Control of bilirubin levels
Anti-D Abs – direct Coombs test
Phototherapy, transfusion
After repeated IUT – newborn usually has mild or middle
anaemia, icterus is usually curable only with phototherapy
without transfusion
The biggest problem – patients with repeated hydrops fetalis
before the 20th week of gestation (no effective treatment)
In 1950s, every 2nd alloimunized woman lost her
baby, very serious problem till 1970s
RhD prophylaxis in RhD negative women –
decrease of perinatal morbidity and mortality
Still Rh alloimmunization is problem because of
No prophylaxis after delivery
No prophylaxis after some other invasive procedures
Low prophylaxis dosage after intensive bleeding
during delivery
Application of anti-D Abs, half-time ~16 days
From the 1960s
Decrease sensibilisation from 8% to 0,8% of all
pregnancies
Only for non-sensitized women (no anti-D Abs in
maternal blood)
Partobulin, Rhega
Administration necessary 72h post-partum or after
sensibilisation event
After delivery: usually 250 – 300 μg intramuscularly
(20 μg anti-D – neutralisation of 1 ml RhD positive blood)
Intensive bleeding (SC)– higher dosage - 500 μg i.m.
Prevents sensibilisation of maternal IS
Application of anti-D Abs – blocks Ag
Foetus (D)
Mother (d)
IgG-anti-D
(prophylaxis)
Prevents Abs production, hemolysis
Next to elimination of fetal erythrocytes (no B cell
activation)
Active supression of B lymphocytes by
immunocomplexes of RhD antigens with binded Abs
BCR a Fc receptors aggregation
Hořejší a Bartůňková, 2001
Necessary application of RhD prophylaxis after:
Delivery of RhD positive child
After miscarriage or abortion
After ectopic pregnancy
After procedures connected with increased
fetomaternal bleeding (invasive procedure)
After bleeding generally (blunt hits into belly)
After transfusion of RhD positive blood
No maternal complication
Still blood preparate – usually from donors
with ↑ anti-D Abs levels
Risk – haemolytic anaemia in foetus,
passage of Abs via placenta and
destruction of fetal erythrocytes
But application of low doses, low risk of fetal
damage
In the case of RhD negative foetus –
no RhD prophylaxis necessary